Canada Latent Tuberculosis Infection Detection Market (By Test Type: Tuberculin Skin Test, Interferon Gamma Release Assays; By End Use; By Province) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Canada Latent Tuberculosis Infection Detection Market 

5.1. COVID-19 Landscape: Canada Latent Tuberculosis Infection Detection Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Canada Latent Tuberculosis Infection Detection Market, By Test Type

8.1. Canada Latent Tuberculosis Infection Detection Market, by Test Type, 2022-2030

8.1.1 Tuberculin Skin Test

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Interferon Gamma Release Assays

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Canada Latent Tuberculosis Infection Detection Market, By End-use

9.1. Canada Latent Tuberculosis Infection Detection Market, by End-use, 2022-2030

9.1.1. Diagnostic Laboratories

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Hospitals/Clinics

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Academic & Research Institutions

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Canada Latent Tuberculosis Infection Detection Market, By Province 

10.1. Canada Latent Tuberculosis Infection Detection Market, by Province, 2022-2030

10.1.1. Alberta

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. British Columbia

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Manitoba

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. New Brunswick

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Nova Scotia

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Ontario

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Prince Edward Island

10.1.7.1. Market Revenue and Forecast (2017-2030)

10.1.8. Quebec

10.1.8.1. Market Revenue and Forecast (2017-2030)

10.1.9. Saskatchewan

10.1.9.1. Market Revenue and Forecast (2017-2030)

10.1.10. Northwest Territories

10.1.10.1. Market Revenue and Forecast (2017-2030)

10.1.11. Nunavut

10.1.11.1. Market Revenue and Forecast (2017-2030)

10.1.12. Yukon

10.1.12.1. Market Revenue and Forecast (2017-2030)

10.1.13. Newfoundland & Labrador

10.1.13.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Canada Latent Tuberculosis Infection Detection Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.1.2. Market Revenue and Forecast, by End-use (2017-2030)

11.1.3. Market Revenue and Forecast, by Province (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Province (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.2.2. Market Revenue and Forecast, by End-use (2017-2030)

11.2.3. Market Revenue and Forecast, by Province (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Province (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by End-use (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Province (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by End-use (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Province (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.3.2. Market Revenue and Forecast, by End-use (2017-2030)

11.3.3. Market Revenue and Forecast, by Province (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Province (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by End-use (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Province (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by End-use (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Province (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Province (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by End-use (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Province (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by End-use (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Province (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.5.3. Market Revenue and Forecast, by Province (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by End-use (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Province (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Test Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by End-use (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Province (2017-2030)

Chapter 12. Company Profiles

12.1. Abbott

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. QIAGEN

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. F. Hoffmann-La Roche Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Sanofi

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Oxford Immunotec USA

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. ARKRAY, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. bioMérieux SA

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms